Prostate Biopsy in India and UAE | Complete Patient Guide

• ELIGIBILITY CRITERIA:

• Men with serum PSA ≥4.0 ng/mL on two consecutive measurements separated by ≥4 weeks, after excluding UTI, prostatitis, or recent instrumentation as confounders

• Men with PSA in the 2.5–4.0 ng/mL 'grey zone' but with elevated PSA density (>0.15 ng/mL/cc), abnormal PSA velocity (>0.75 ng/mL/year), or unfavourable free-to-total PSA ratio (<25%)

• Men with any palpable abnormality on digital rectal examination (nodule, induration, or asymmetry) regardless of PSA level

• PI-RADS 3, 4, or 5 lesions identified on multiparametric MRI (mpMRI) of the prostate

• Men on active surveillance for low-risk prostate cancer requiring confirmatory or surveillance biopsy per PRIAS, PROTECT, or institutional protocols

• Prior negative biopsy with persistently rising PSA or clinical suspicion of anterior/transition zone tumour missed by standard TRUS sampling

• Men with elevated 4Kscore (>7.5%), positive SelectMDx, or ExoDx Prostate (IntelliScore) ≥15.6 where local risk stratification supports biopsy

• REQUIRED PRE-PROCEDURE INVESTIGATIONS:

• Serum PSA (total, free, free-to-total ratio), PSA density calculation using prostate volume on MRI or TRUS

• Multiparametric MRI prostate (T2W, DWI/ADC, DCE sequences) with PI-RADS v2.1 reporting — mandatory before biopsy in all de novo cases

• PSMA PET-CT (e.g., 68Ga-PSMA-11 or 18F-DCFPyL) in high-risk or biochemically recurrent presentations where staging concurrent with diagnosis is clinically indicated

• Complete blood count, coagulation profile (PT/INR, aPTT), renal function panel (eGFR), urine culture and sensitivity (must be sterile before transrectal biopsy)

• Urine flow rate and post-void residual volume to baseline lower urinary tract function

• Digital rectal examination by a consultant urologist

• CONTRAINDICATIONS (ABSOLUTE):

• Active urinary tract or prostatic infection (procedure must be deferred until culture-negative)

• Uncorrectable coagulopathy (INR >1.5 or platelet count <50,000/μL despite optimisation)

• Acute anal or rectal pathology precluding transrectal probe insertion (transperineal approach remains feasible)

• CONTRAINDICATIONS (RELATIVE / REQUIRING CASE-BY-CASE ASSESSMENT):

• Active anticoagulation with warfarin, direct oral anticoagulants (DOACs), or dual antiplatelet therapy — requires structured bridging protocol with cardiology/haematology clearance

• Severe anorectal stenosis or prior low anterior resection (transperineal approach preferred)

• Significant immunosuppression (increased sepsis risk with transrectal route; transperineal approach preferred)

• Latex allergy (latex-free probes and gloves mandatory)

APPROACH 1 — TRANSPERINEAL PROSTATE BIOPSY (PREFERRED, CURRENT GOLD STANDARD)

In the transperineal (TP) approach, biopsy needles are introduced through the perineal skin (the area between the scrotum and the anus) under local anaesthesia (LA-TP), sedation, or general anaesthesia, entirely avoiding the rectal lumen. This eliminates rectal flora from the needle path and reduces the risk of post-biopsy sepsis to <0.1% (versus 2–3% with transrectal biopsy), as confirmed in the landmark TREXIT and LOTUS randomised trials. Platforms available in leading Indian and UAE centres include:

• Free-hand transperineal biopsy under local anaesthetic perineal block (LA-TP) — performed in an outpatient/day-care setting with a biplane TRUS probe and 18G co-axial biopsy needle

• Template/mapping transperineal biopsy (saturation biopsy, 24–40 cores) — used in active surveillance confirmation and when prior TRUS-Bx was negative; performed under general or spinal anaesthesia

• MRI-TRUS cognitive fusion transperineal biopsy — the urologist mentally registers MRI lesion coordinates to real-time ultrasound; widely available; no additional hardware cost

• Software-based MRI-TRUS fusion transperineal biopsy (e.g., UroNav, BioJet, Koelis Trinity, Artemis platforms) — real-time electromagnetic or image-registration software overlays mpMRI targets onto live TRUS, enabling reproducible targeted core placement within ≤2.4 mm accuracy

APPROACH 2 — TRANSRECTAL ULTRASOUND-GUIDED BIOPSY (TRUS-Bx, CONVENTIONAL)

A biplane TRUS probe is inserted rectally; systematic 12-core biopsy (sextant + lateral) is performed with an 18G spring-loaded biopsy gun. This approach remains available at many centres for patients with low sepsis risk, and is augmented by cognitive or software MRI-fusion for targeted sampling. Pre-procedure rectal preparation with a betadine enema and prophylactic fluoroquinolone (or, in fluoroquinolone-resistant environments, an augmented antibiotic protocol using fosfomycin or cephalosporins per local antimicrobial stewardship guidelines) is mandatory. Due to rising fluoroquinolone-resistant E. coli sepsis rates globally, the EAU 2024 guidelines now actively recommend transperineal over transrectal access where local anaesthesia capability exists.

APPROACH 3 — IN-BORE MRI-GUIDED PROSTATE BIOPSY (MRI-TRUS FUSION DIRECT / REAL-TIME 3T MRI BIOPSY)

Performed inside a 3-Tesla MRI scanner using MRI-compatible needles and real-time T2-weighted or DWI imaging for direct lesion targeting. This approach offers the highest spatial accuracy for PI-RADS 4–5 lesions in the anterior, transition zone, or apex—locations historically undersampled by standard TRUS. Available at select centres in Mumbai, Hyderabad, Delhi NCR, Dubai, and Abu Dhabi. Significantly higher cost; procedure time 60–90 minutes; generally performed under moderate sedation.

APPROACH 4 — ROBOTIC ULTRASOUND-ASSISTED BIOPSY (EMERGING)

Platforms such as the iSR'obot Mona Lisa (Biobot Surgical) use robotic arm-mounted TRUS with AI-driven trajectory planning and real-time needle guidance, enabling consistent reproducible sampling at pre-planned coordinates. Pilot data show detection rates for clinically significant cancer (csPCa, defined as Gleason Grade Group ≥2, ISUP 2017) comparable to or exceeding conventional MRI-fusion. Available at select academic centres in Bangalore, Gurugram, and Dubai Healthcare City.

BIOPSY CORES AND PATHOLOGY REPORTING:

Regardless of approach, all cores are processed for haematoxylin-and-eosin (H&E) histopathology and reported using the 2019 WHO/ISUP Grading System (Gleason Grade Groups 1–5). ERG, PTEN, and Ki-67 immunohistochemistry, as well as tissue-based genomic tests (Prolaris, Decipher, Oncotype DX GPS) may be added for prognostic stratification in localised disease at the treating pathologist's discretion or upon oncology team request.

PRE-ARRIVAL (2–4 WEEKS BEFORE PROCEDURE):

• GAF Healthcare coordinator collects all prior records: PSA history, mpMRI report and DICOM images, DRE findings, relevant blood tests

• Remote teleconsultation with the assigned consultant urologist (typically an onco-urologist or uro-oncologist with >500 prostate biopsy volume per year) to review imaging, confirm indication, and determine optimal biopsy approach (transperineal vs. TRUS-fusion vs. in-bore MRI)

• Pre-biopsy checklist issued: cessation of aspirin (5–7 days), clopidogrel (7 days), warfarin (5 days with INR <1.5 on day of procedure), DOACs (48 hours for rivaroxaban/apixaban; 72 hours for dabigatran, adjusted for eGFR); anticoagulation bridging plan provided if clinically indicated

• Urine culture collected and confirmed sterile; antibiotic prophylaxis regimen prescribed per local ASP protocol

• e-Medical Visa (India) or UAE entry visa arranged by GAF Healthcare; airport transfer and accommodation booked

DAY OF ARRIVAL (DAY 0):

• Airport transfer to partner hospital or hotel (procedures are frequently day-care; patient may check into hotel first)

• Pre-procedure nursing assessment: blood pressure, review of medication cessation compliance, final urine culture review, consent documentation

PROCEDURE DAY (DAY 1):

• Patient fasts for 4–6 hours if sedation or general anaesthesia planned (LA-TP cases may eat lightly)

• Perineal/rectal area cleaned; IV access established; antibiotic prophylaxis administered IV (e.g., cefazolin 1g IV for transperineal, or targeted rectal swab-guided antibiotic for transrectal)

• For LA-TP: periprostatic nerve block (10 mL 1% lidocaine bilaterally under TRUS guidance); procedure performed with patient in lithotomy position; 12–24 targeted + systematic cores obtained; duration 20–40 minutes

• For general/spinal anaesthesia cases (template biopsy, in-bore MRI): transfer to operating theatre or MRI suite; procedure duration 45–90 minutes

• Recovery room observation 1–2 hours; voiding trial confirmed before discharge

• Day-case patients discharged same afternoon with written instructions; overnight stay patients admitted to urology ward

DAY 2–3 (EARLY RECOVERY):

• Oral antibiotics continued (typically 3–5 days; fluoroquinolone or fosfomycin per ASP protocol)

• Patient counselled to expect haematuria (blood in urine) for up to 2–4 weeks, haematospermia (blood in semen) for up to 6–8 weeks, and minor perineal discomfort for 3–5 days — all expected sequelae, not complications

• Adequate oral hydration (≥2L/day) recommended to flush the urinary tract

• Alpha-blocker (e.g., tamsulosin 0.4 mg OD) prescribed if lower urinary tract symptoms (LUTS) or temporary urinary retention risk is elevated

• Strenuous physical activity, sexual intercourse, and heavy lifting avoided for 5–7 days

• GAF coordinator performs daily welfare check (phone/WhatsApp)

DAY 3–5 (FIT-TO-FLY ASSESSMENT):

• Urologist reviews patient in clinic or via teleconsult: confirms cessation of frank haematuria, haemodynamic stability, absence of fever or sepsis signs, successful voiding

• Short-haul flights (<4 hours): typically cleared from Day 3–4

• Long-haul international flights: cleared from Day 5–7 once antibiotics are completed and urinary symptoms are stable

• GAF Healthcare provides a fit-to-fly medical certificate and all histopathology reports in digital format

DAY 10–14 (BIOPSY RESULTS AND REMOTE ONCOLOGY CONSULTATION):

• Final histopathology report (H&E, Gleason Grade Group, percentage core involvement, perineural invasion) issued by the pathology laboratory

• Remote multidisciplinary team (MDT) discussion with urologist ± medical oncologist ± radiation oncologist conducted via secure video link

• Management plan communicated in writing: active surveillance protocol, radical prostatectomy workup, referral for radiation oncology assessment, or systemic therapy initiation as appropriate

• Patient supported in sharing findings with their home-country physician; GAF coordinator facilitates record transfer